| |
Are you thinking about launching a study? Or are you in the middle of managing a biopharma project? Learn more about the major risks surrounding your work and the best ways to manage your project for success. Download the App Note here. 
|
|
Today's Big NewsNov 1, 2022 |
| By Nick Paul Taylor Pfizer has halted a pivotal trial of its respiratory syncytial virus vaccine candidate early for efficacy, positioning it to file for approval by the end of the year. But with the study only meeting one of its two primary endpoints, the top-line result leaves scope to question how Pfizer will fare against AstraZeneca and Sanofi’s rival antibody. |
|
|
|
By Max Bayer Lilly is exuding optimism as the race to develop a breakthrough Alzheimer's treatment hits the home stretch. The company is hoping to stay neck-and-neck with Eisai after the latter turned heads with its phase 3 lecanemab data. |
By Annalee Armstrong With compliments to its peer drugmakers developing other oral ALK-2 inhibitors, BioCryst is stepping back from the effort to produce a therapy for an ultra-rare bone disease—and keeping $100 million in its pocket for other priorities. |
Sponsored by Fortress Biotech With 9 marketed products and 20 clinical programs, Fortress Bio’s business model is designed to decrease risk and expense while creating a regular flow of value-creating events for shareholders. |
By James Waldron While Eli Lilly celebrated a “solid quarter” of earnings this morning, a look over the Big Pharma’s third-quarter presentation reveals that the company has quietly dumped two clinical-stage assets. |
Sponsored by By: Fierce Biotech Fierce Biotech sits down with biotech and drug development leaders as they discuss the latest breakthroughs and innovations driving the life sciences industry. These videos explore what's next for the biotech industry and how companies are delivering value to patients and customers in today's evolving healthcare landscape. |
By Nick Paul Taylor Pfizer has tossed out three R&D programs after sifting through the latest data on its early-phase pipeline, adding projects focused on atopic dermatitis, nonalcoholic steatohepatitis (NASH) and breast cancer to its discard pile. |
By Max Bayer HI-Bio is hitting the scene with $120 million in cash and two clinical-stage assets from MorphoSys acquired in June. The company is developing a slate of precision therapies aimed at cellular drivers of immune-mediated diseases. |
By Annalee Armstrong Unity Biotechnology seems to have gotten its crew together behind a common goal in ophthalmology, with the biotech announcing today that its treatment for diabetic macular edema improved vision in a mid-stage trial. |
By Helen Floersh Generations of studying the root cause of schizophrenia have largely converged around a single theory: the “dopamine hypothesis,” which postulates that a combination of genetic susceptibility, substance abuse and environmental stress lead to too much dopamine signaling in the brain. Scientists now believe they've identified the mechanism that underlies the dopamine hypothesis of schizophrenia. |
By Nick Paul Taylor Eli Lilly is plowing a further $50 million into its research collaboration with Purdue University, signing up to work with its partner for another five years on challenges including intrathecal and nanoparticle drug delivery. |
By Kevin Dunleavy Drug shortages aren’t going away any time soon, according to Bindiya Vakil, CEO of Resilinc, a California-based firm that helps companies from a variety of industries mitigate supply chain problems. While shortages of high-profile drugs such as Adderall and amoxicillin have garnered headlines recently, Vakil points to a recent FDA warning that has the potential for more far-reaching consequences. |
By Dave Muoio Healthcare lobbying increased from $358.2 million in 2000 to $713.6 million after adjusting for rising prices, researchers wrote in JAMA Health Forum. Pharmaceuticals/health product manufacturers and healthcare providers were responsible for most of the gains. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we dig into rumors of a shaky relationship between Biogen and Eisai. We also chat about AZ’s ability to finally tout the approval of an asset that’s seen many failures over the years. |
|
|---|
|
|
|
Tuesday, November 8, 2022 | 12:30pm ET / 9:30am PT As a partner in the overall health ecosystem, Myriad Genetics is combining de-identified genetic data with indications, phenotypes, and outcomes to power the next generation of precision medicine advancements. Register now. 
|
|
Whitepaper Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Research Learn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
